Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance
- PMID: 12851873
- DOI: 10.1016/s0016-5085(03)00668-1
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance
Abstract
Background & aims: Acute hepatitis C virus infection accounts for approximately 20% of cases of acute hepatitis today. The aim of this study was to define the natural course of the disease and to contribute to the development of treatment strategies for acute hepatitis C virus.
Methods: The diagnosis of acute hepatitis C virus in 60 patients was based on seroconversion to anti-hepatitis C virus antibodies or clinical and biochemical criteria and on the presence of hepatitis C virus RNA in the first serum sample.
Results: Fifty-one of 60 (85%) patients presented with symptomatic acute hepatitis C virus. In the natural (untreated) course of acute symptomatic hepatitis C (n = 46), spontaneous clearance was observed in 24 patients (52%), usually within 12 weeks after the onset of symptoms, whereas all asymptomatic patients (n = 9) developed chronic hepatitis C. The start of antiviral therapy (interferon-alpha with or without ribavirin) beyond 3 months after the onset of acute hepatitis induced sustained viral clearance in 80% of treated patients.
Conclusions: The management of acute hepatitis C has to take into account the high rate of spontaneous viral clearance within 12 weeks after the onset of symptomatic disease. Treatment of only those patients who remain hepatitis C virus RNA positive for more than 3 months after the onset of disease led to an overall viral clearance (self-limited and treatment induced) in 91% of patients, and unnecessary treatment was avoided in those with spontaneous viral clearance. Patients with asymptomatic acute hepatitis C virus infection are unlikely to clear the infection spontaneously and should be treated as early as possible.
Comment in
-
New insights into acute hepatitis C.Gastroenterology. 2003 Jul;125(1):253-6. doi: 10.1016/s0016-5085(03)00807-2. Gastroenterology. 2003. PMID: 12851890 Review. No abstract available.
-
Acute hepatitis C virus infection: to treat or not to treat?Gastroenterology. 2004 Apr;126(4):1219-20; author reply 1220. doi: 10.1053/j.gastro.2004.02.041. Gastroenterology. 2004. PMID: 15057772 No abstract available.
Similar articles
-
[Epidemic outbreak of acute hepatitis C--clinical course, histology and effectiveness of therapy].Przegl Epidemiol. 2005;59(2):385-94. Przegl Epidemiol. 2005. PMID: 16190545 Polish.
-
Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.Eur J Gastroenterol Hepatol. 2010 Mar;22(3):278-88. doi: 10.1097/MEG.0b013e32832c7b2e. Eur J Gastroenterol Hepatol. 2010. PMID: 19550347
-
Symptomatic acute hepatitis C in Egypt: diagnosis, spontaneous viral clearance, and delayed treatment with 12 weeks of pegylated interferon alfa-2a.PLoS One. 2008;3(12):e4085. doi: 10.1371/journal.pone.0004085. Epub 2008 Dec 30. PLoS One. 2008. PMID: 19115010 Free PMC article.
-
[Treatment of hepatitis C virus infection].Praxis (Bern 1994). 2005 May 4;94(18):721-6. doi: 10.1024/0369-8394.94.18.721. Praxis (Bern 1994). 2005. PMID: 15938383 Review. German.
-
Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients.AIDS. 2006 May 12;20(8):1157-61. doi: 10.1097/01.aids.0000226956.02719.fd. AIDS. 2006. PMID: 16691067 Review.
Cited by
-
Development of a Multiple-Epitope-Based Vaccine for Hepatitis C Virus Genotypes 1a and 1b: an in-silico reverse vaccinology approach.In Silico Pharmacol. 2024 Nov 9;12(2):100. doi: 10.1007/s40203-024-00275-4. eCollection 2024. In Silico Pharmacol. 2024. PMID: 39524457
-
Biomarkers in Detection of Hepatitis C Virus Infection.Pathogens. 2024 Apr 17;13(4):331. doi: 10.3390/pathogens13040331. Pathogens. 2024. PMID: 38668286 Free PMC article. Review.
-
Cytokine profile and viral diversity in the early seronegative stage of community-acquired hepatitis C virus (HCV) infection.Sci Rep. 2023 Nov 16;13(1):20045. doi: 10.1038/s41598-023-47335-x. Sci Rep. 2023. PMID: 37973814 Free PMC article.
-
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S262-S269. doi: 10.1093/cid/ciad362. Clin Infect Dis. 2023. PMID: 37579209 Free PMC article.
-
RT-LAMP-Based Molecular Diagnostic Set-Up for Rapid Hepatitis C Virus Testing.Biosensors (Basel). 2022 May 5;12(5):298. doi: 10.3390/bios12050298. Biosensors (Basel). 2022. PMID: 35624599 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
